Kindred Biosciences Profit Margin

Kindred Biosciences (KIN) currently reports a profit margin of -550.38% as of June 2021. That compares with -70.56% in the prior-year period — down 680.0% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore Kindred Biosciences's profit margin history and peer comparisons.

Kindred Biosciences's profit margin decreased from -70.56% to -550.38% — a 680.0% year-over-year decrease (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Kindred Biosciences's profit margin of -550.38% is lower than the Healthcare sector average of 13.89%. That is roughly 4061.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Kindred Biosciences's current -550.38% should be judged against Healthcare norms (sector average: 13.89%) and against KIN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -550.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Kindred Biosciences, and consider following KIN for alerts when major investors trade the stock.